“We are excited that Indego is now available for a much larger number of patients in the United States, enabling stroke patients to have access to this novel gait therapy,” said Achilleas Dorotheou, head of the human motion and control business unit for Parker.
The recent FDA clearance came after the completion of a large, multi-site clinical trial involving eight rehabilitation centers in the U.S., where a broad range of stroke patients received gait therapy with Indego and its therapy software suite.
“With the Therapy+ Software Suite, Indego can be used to provide individualized and patient-centric training, which is of critical importance for successful gait therapy sessions with stroke patients,” said Dr. Karen Nolan from the
Indego is a state-of-the-art rehabilitation and assistive technology designed to improve patient mobility and independence while offering clinicians a meaningful therapy tool. Indego has received FDA Clearance and CE Mark, allowing it to be sold commercially in the U.S. and Europe. Indego has also earned a UL Mark which was obtained through extensive testing to certify the high standards of the Indego system design, function, and safety. To learn more about Indego visit www.indego.com
About Parker Hannifin
Parker Hannifin is a Fortune 250 global leader in motion and control technologies. For 100 years the company has engineered the success of its customers in a wide range of diversified industrial and aerospace markets. Learn more at www.parker.com or @parkerhannifin.
Media – Aidan Gormley, Director,
Global Communicationsand Branding 216/896-3258 firstname.lastname@example.org